Factor VII Light Chain-targeted Lidamycin Shows Intensified Therapeutic Efficacy for Liver Cancer

Overview

Journal Cancer Biother Radiopharm

Specialties Oncology
Pharmacology
Radiology

Date 2012 Jun 2

PMID 22651685

Citations 3

Authors

Qing Zhang

Xiujun Liu

Shuangshuang Xu

Caihong Li

Yang Zhang

Jie Yang

Junnian Zheng

Affiliations

Soon will be listed here.

Abstract

The overexpression of tissue factor (TF) observed in numerous cancer cells and clinical samples of human cancers makes TF an ideal target for cancer therapy. The purpose of this study is to develop a TF-targeting energized fusion protein hlFVII-LDP-AE, which is composed of a human Factor VII light chain (hlFVII) as the targeting domain conjugated to the cytotoxic antibiotic lidamycin (LDM, LDP-AE) as the effector domain. The potential efficacy of hlFVII-LDP-AE for cancer therapy was tested in vitro by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and colony formation assays and in vivo with a BALB/c nude mouse xenograft model of human liver cancer line HepG2. The inhibitory concentration (IC(50)) value of hlFVII-LDP-AE varied from 0.15 to 0.64 nM for the various human tumor lines. hlFVII-LDP-AE showed a tumor growth inhibition rate of 90.6% at the dose of 0.6 mg/kg in in vivo animal experiments. The mechanism through which hlFVII-LDP-AE inhibits tumor growth also was determined by Hoechst 33342 staining and Tdt-mediated dUTP nick-end labeling (TUNEL) assay. hlFVII-LDP-AE causes tumor cell death through inducing chromatin condensation and cleavage of genomic DNA. These findings suggest that the hlFVII-LDP-AE protocol is efficacious and tolerated in the mouse model of human liver cancer HepG2 and has clinical applicability for treating cancer patients.

Citing Articles

Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.

Zhang Y, Yang J, Ding M, Li L, Lu Z, Zhang Q Oncol Lett. 2016; 12(5):3241-3249.

PMID: 27899989 PMC: 5103927. DOI: 10.3892/ol.2016.5081.

A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.

Zhang Q, Zhang Y, Li K, Wang H, Li H, Zheng J PLoS One. 2015; 10(6):e0129865.

PMID: 26066322 PMC: 4466375. DOI: 10.1371/journal.pone.0129865.

Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma.

Zhang Q, Liu X, Li C, Liao D, Ouyang Z, Zheng J Oncol Lett. 2013; 6(3):801-806.

PMID: 24137414 PMC: 3789075. DOI: 10.3892/ol.2013.1437.

References

Callander N, Varki N, Rao L . Immunohistochemical identification of tissue factor in solid tumors. Cancer. 1992; 70(5):1194-201. DOI: 10.1002/1097-0142(19920901)70:5<1194::aid-cncr2820700528>3.0.co;2-e. View

Williams J, Weitman S, Gonzalez C, Jundt C, Marty J, Stringer S . Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res. 2001; 7(3):724-33. View

Hu J, Xue Y, Xie M, Zhang R, Otani T, Minami Y . A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo). 1988; 41(11):1575-9. DOI: 10.7164/antibiotics.41.1575. View

Hagen F, Gray C, OHara P, Grant F, Saari G, Woodbury R . Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci U S A. 1986; 83(8):2412-6. PMC: 323307. DOI: 10.1073/pnas.83.8.2412. View

Xin C, Ye S, Ming Y, Shenghua Z, Qingfang M, Hongxing G . Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM. Gene Ther. 2010; 17(10):1234-43. DOI: 10.1038/gt.2010.76. View

Hu Z, Rao B, Chen S, Duanmu J . Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer. 2010; 10:235. PMC: 2882923. DOI: 10.1186/1471-2407-10-235. View

Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y . Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol. 2006; 11(3):167-75. DOI: 10.1007/s10147-006-0580-7. View

Weitman S, Marty J, Jolivet J, Locas C, Von Hoff D . The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res. 2000; 6(4):1574-8. View

McHugh M, Gawron L, Matsui S, Beerman T . The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res. 2005; 65(12):5344-51. DOI: 10.1158/0008-5472.CAN-05-0015. View

10.

Hu Z, Rao B, Chen S, Duanmu J . Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer. Breast Cancer Res Treat. 2010; 126(3):589-600. PMC: 3951776. DOI: 10.1007/s10549-010-0957-1. View

11.

Jiang B, Li D, Zhen Y . Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells. Biochem Biophys Res Commun. 1995; 208(1):238-44. DOI: 10.1006/bbrc.1995.1329. View

12.

Wang Z, He Q, Liang Y, Wang D, Li Y, Li D . Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells. Biochem Pharmacol. 2003; 65(11):1767-75. DOI: 10.1016/s0006-2952(03)00117-5. View

13.

Hu Z, Garen A . Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci U S A. 2000; 97(16):9221-5. PMC: 16849. DOI: 10.1073/pnas.97.16.9221. View

14.

Tanaka T, Hirama M, Otani T . Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol. 2001; 309(1):267-83. DOI: 10.1006/jmbi.2001.4621. View

15.

Wilcox J, Smith K, Schwartz S, Gordon D . Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989; 86(8):2839-43. PMC: 287014. DOI: 10.1073/pnas.86.8.2839. View

16.

Allen T . Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2(10):750-63. DOI: 10.1038/nrc903. View

17.

Zhen Y, Ming X, Yu B, Otani T, Saito H, Yamada Y . A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo). 1989; 42(8):1294-8. DOI: 10.7164/antibiotics.42.1294. View

18.

Zhong G, Zhang S, Li Y, Liu X, Gao R, Miao Q . A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. Cancer Lett. 2010; 295(1):124-33. DOI: 10.1016/j.canlet.2010.02.020. View

19.

Rak J, Milsom C, Magnus N, Yu J . Tissue factor in tumour progression. Best Pract Res Clin Haematol. 2009; 22(1):71-83. DOI: 10.1016/j.beha.2008.12.008. View

20.

Tang Y, Borgstrom P, Maynard J, Koziol J, Hu Z, Garen A . Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther. 2007; 14(4):346-53. DOI: 10.1038/sj.cgt.7701030. View